Table 1 Daily food-intake (g).

From: Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats

Weeks

Control group (n = 20)

Sham operation group (n = 20)

Model group (n = 20)

Treatment group (n = 20)

3

19.15 ± 0.07

19.23 ± 0.09

19.18 ± 0.07

19.21 ± 0.06

4

23.58 ± 0.08

23.67 ± 0.11

21.26 ± 0.09

21.59 ± 0.08

5

28.01 ± 0.14*

27.39 ± 0.12^

18.75 ± 0.08

17.98 ± 0.07

6

29.14 ± 0.13#

29.59 ± 0.14&

17.03 ± 0.05

16.89 ± 0.06

7

31.23 ± 0.12$

30.78 ± 0.13@

16.29 ± 0.06

17.11 ± 0.05

  1. *P < 0.05 compared with the model group.
  2. ^P < 0.05 compared with the model group.
  3. #P < 0.05 compared with the model group.
  4. &P < 0.05 compared with the model group.
  5. $P < 0.05 compared with the model group.
  6. @P < 0.05 compared with the model group. After 4 weeks the rats in model group and treatment group ate less, due to the formation and progression of hilar cholangiocarcinoma, bile secretion is blocked and dyspepsia occurs, their food intake is significantly reduced compared with the other two groups. However, after GW4064 treatment, the food intake of the treatment group increased slightly in the seventh week.
Back to article page